| Genetic Testing May Spot Disease Risk Doctors are turning to genetic testing to identify and prevent heart problems in patients who are healthy yet possibly at risk because of a family history. online.wsj.com |
Aetna Finds Flaw in Rate Aetna withdrew its request for an average 19% increase in California individual-policy health insurance rates, the second company to do so, after discovering miscalculations. online.wsj.com |
Dr. Reddy's Profit Retreats 14% Indian drug maker Dr. Reddy's reported a steeper-than-expected 14% drop in first-quarter consolidated net profit, dragged down mainly by lower sales in the North American market. online.wsj.com |
Alexza Pharma Still Has Room to Rise M.E. Garza submits: With an FDA decision due in early October, Alexza Pharmaceuticals' (ALXA) stock has been reacting very nicely in anticipation, making a string of higher highs and higher lows since early August.Last week, the Company issued a press release announcing that it will participate in two investor conferences, one at the Rodman & Renshaw Annual Global Investment Conference tomorrow, September 14, 2010 at 3:40 p.m. ET, and the other at the JMP Securities Healthcare Conference on Monday, September 27, 2010 at 2:00 p.m. ET.Complete Story » seekingalpha.com |
FDA Warns Gilead About Manufacturing Problems: How Serious Is It? Pharmalot submits: Gilead Sciences (GILD) just can’t get it right. Earlier this year, the FDA inspected its San Dimas, California, facility, which yielded a so-called 483 inspectional report citing various problems with the agency’s Good Manufacturing Practices. The biotech responded but to no avail. The FDA has now issued a warning letter and Gilead may be forced to curtail exports of the AmBisome antifungal treatment. The problems, which were noted in a filing with the US Securities and Exchange Commission, include control systems and monitoring, procedures to prevent microbiological contamination and preventative cleaning and equipment maintenance. Quality procedures and controls were also noted for certain lots of the Viread AIDS med and the overall “effectiveness” of the plant in carrying out its responsibilities. Not a good showing.Complete Story » seekingalpha.com |